reduce aortic regurgitation (AR) and vascular complications in transcatheter aortic valve implantation. Aim of this study is to compare the outcomes of the S3-THV with the preceding Sapien XT THV (SXT-THV) in patients who underwent transcatheter aortic valve implantation for symptomatic severe native aortic stenosis. Methods and Results-Eligible patients were retrospectively identified in our institutional database and periprocedural clinical and imaging data were collected. Non-parsimonious one-to-many propensity score matching was performed to account for differences in baseline characteristics. Between November 2011 and December 2014, 167 patients underwent balloon-expandable transcatheter aortic valve implantation with either the S3-THV (n=49) or SXT-THV (n=118). Fortyfour (89.8%) S3-THV patients were matched to 66 (55.9%) SXT-THV patients (mean age 80.3±8.4 and 80.5±7.8 years, median EuroSCORE 15.8 and 16.5%, respectively). In the S3-THV and SXT-THV groups, transfemoral approach (77.3% versus 78.8%) and postdilatation rates (15.9% versus 12.1%) were similar. Predischarge echocardiography demonstrated a lower incidence of ≥mild AR (15.9% versus 46.2%, P=0.003) for the S3-THV, despite reduced annulus area to prosthesis oversizing (8.2±5.1 versus 18.2±10.7%, P=0.001). Transfemoral access site-related life-threatening or major bleedings and vascular complications were absent in the S3-THV group (0% versus 7.7%, P=0.15). No differences were observed in pacemaker implantation rate (9.8% versus 8.8%, P=0.94) and 30-day mortality (both 5%). Conclusions-In this retrospective, propensity score-matched analysis, the S3-THV performed superiorly to the SXT-THV, as demonstrated by improved valve patency and increased transfemoral access safety. (Circ Cardiovasc Interv. 2015;8:e002408.
T ranscatheter aortic valve implantation (TAVI) has become a firmly established treatment option for symptomatic severe aortic stenosis (AS) in inoperable patients 1 and patients at high operative risk. 2, 3 Although proven noninferior to surgical aortic valve replacement in terms of all-cause mortality, TAVI is associated with a higher incidence of postoperative aortic regurgitation (AR) and vascular complications. 2, 3 Other non-negligible TAVI-related complications are cerebral embolic events and advanced conduction disturbances. 4 The extension of TAVI to lower risk populations requires minimization of these adverse events, partly depending on technological developments in transcatheter heart valves (THVs) and delivery systems.
Recently, the new balloon-expandable Sapien 3 THV (S3-THV; Edwards Lifesciences, Irvine, CA) has become commercially available. 5 The S3-THV embodies the next generation balloon-expandable valve of the Sapien valve family, building on the clinical experiences gained with the previous Sapien XT-THV (SXT-THV; Edwards Lifesciences). With its new features, including an outer annular sealing cuff, improved delivery system, and low crimped profile, the S3-THV is thought to achieve better results than the preceding SXT-THV. 5 Initial data from a multicenter registry prospectively evaluating the S3-THV looked promising, reporting low rates of AR, vascular complications, and stroke. 6 Comparative studies on the clinical outcomes of TAVI with the S3-THV and SXT-THV are currently scarce.
Aim of this study was to retrospectively compare the hemodynamic and clinical outcomes of TAVI with the S3-THV versus the SXT-THV in patients with symptomatic severe native AS.
Methods
This is a retrospective single-center study. All patients who underwent TAVI for severe native AS at the University Medical Center Utrecht by means of S3-THV or SXT-THV implantation were identified in our institutional database and included in the study. Implantation of the SXT-THV had to be state-of-the-art, meaning performed with the Novaflex+ delivery system through an expandable sheath. Patients with bicuspid aortic valve anatomy or a degenerated surgical aortic valve were excluded from the study.
Patients were selected for TAVI based on Heart Team discussion involving at least one interventional cardiologist and one cardiac surgeon. Reasons to refrain from surgical aortic valve replacement included high operative risk (logistic EuroSCORE-I≥15%) and the presence of contraindications (eg, porcelain aorta, frailty, patent grafts in proximity of the sternum). Workup of TAVI candidates included transthoracic echocardiography (TTE), coronary angiography, thoracic and abdominal multislice computed tomography, and consultation of the geriatrics department.
Relevant periprocedural clinical and imaging data were collected and registered in a database. Follow-up was obtained using documentation of standard-of-care outpatient visits, and survival status was attained by interrogation of the Dutch municipal personal records database. Outcomes were registered in compliance with the Valve Academic Research Consortium 2 (VARC-2) criteria. Device success was defined accordingly as the proper implantation of the first valve prosthesis used, with intended performance of the valve (peak aortic flow velocity <3 m/s and no moderate or severe AR) and no procedural mortality. Vascular complications were documented for all procedural access sites, defined as any location traversed by a guidewire, a catheter, or a sheath during the procedure, including arteries, veins, left ventricular apex, and the aorta.
All patients gave informed consent for the TAVI procedure, and the study was performed under a waiver obtained from the institutional medical ethics committee (14-661/C).
Echocardiographic, Angiographic, and Multislice Computed Tomography Evaluation
All patients underwent TTE examination one day before TAVI and before discharge. Native valve function was assessed according to the guidelines. 7, 8 Left ventricular ejection fraction was measured by the modified Simpson's biplane method or, in case of insufficient image quality, visually estimated and quantified in incremental steps of 5%. Prosthetic valve function was evaluated as recommended. Left ventricular outflow tract (LVOT) diameter measurements and Doppler velocity recordings for calculation of the effective orifice area were performed just beneath the ventricular margin of the prosthetic stent, as previously validated. 9 AR severity (both trans-and paraprosthetic) was assessed and classified by means of the integrative approach endorsed by the VARC-2 recommendations. 10 Angiographic assessment of AR severity was performed according to the Sellers classification, 11 directly after valve implantation and after any countermeasures to address significant AR. Measurements of implantation depth and skewness of valve position were performed on angiographic images as previously described (see Figure in Data Supplement). 12 Implantation depth is presented both in percentages of stent frame height extending below the annulus plane and in millimeters. All measurements were performed by operators experienced in angiographic evaluations and independent from the procedure itself.
Preprocedural multislice computed tomography evaluation included measurement of the aortic annulus and aortic root dimensions and eligibility assessment of the TAVI access sites. Aortic annulus dimensions (minimum diameter, maximum diameter, perimeter, and area) were measured according to standard procedures using dedicated software (3Mensio; Pie Medical Imaging, Maastricht, The Netherlands). Valve prosthesis size was selected in accordance with the manufacturer's recommendations ( Figure 1 ).
Valve Devices
The SXT-THV and its new iteration, S3-THV, are both balloon-expandable valves that consist of a trileaflet bovine pericardial valve sewn into a cobalt-chromium frame. The lower two-thirds of the frame are covered with an internal polyethylene terephthalate skirt. New feature to the S3 is the external polyethylene terephthalate sealing cuff designed to improve apposition with the aortic annulus and minimize paravalvular leakage. Other improvements to the S3-THV are the enhanced frame geometry that allows lower delivery profiles and the higher radial strength for better maintenance of circularity after deployment. 13 Both the SXT-THV and S3-THV valves are available in the sizes 23-mm, 26-mm, and 29-mm, whereas currently only the SXT-THV has a 20-mm version to accommodate small annuli. In the transfemoral approach, the SXT-THV and S3-THV valves are implanted with the NovaFlex+ and Commander delivery systems, respectively, introduced through expandable sheaths (eSheath; Edwards Lifesciences). In transapical or direct aortic procedures, the SXT-THV and S3-THV are deployed with the Ascendra and Certitude delivery systems, respectively. New refinement to the transfemoral S3-THV delivery system is a fine alignment wheel that allows small changes to prosthesis position without having to push or pull the whole delivery system, increasing positioning precision. Device characteristics and sizing charts for the SXT-THV and S3-THV are provided in Figure 1 .
Implantation Procedure and Technique
Valve implantation was performed per transfemoral, transaortic, or transapical approach, in order of our institutional preference, depending on the presence of suitable access sites. Common access techniques were used. All transfemoral procedures involved a full percutaneous technique. Suture-mediated closure devices (Perclose ProGlide; Abbott Laboratories, Abbott Park, IL) were inserted into the femoral arteries to facilitate vascular closure. Conscious sedation was the default anesthetic method in transfemoral procedures; in surgical TAVI, general anesthesia was instituted. Fluoroscopic guidance was used to guide prosthesis positioning and deployment, whereas intraprocedural imaging support was accounted for by intracardiac echocardiography in the transfemoral and transesophageal echocardiography in surgical TAVI procedures. After routine predilatation to prepare the device landing zone, valve implantation was performed under rapid ventricular pacing (180-200 bpm) by means of a 2-step inflation technique, as previously described for SXT-THV. 12 The S3-THV was deployed
WHAT IS KNOWN
• The new Sapien 3 is designed to reduce aortic regurgitation and vascular complications after transcatheter aortic valve implantation, with its annular sealing cuff and lower delivery profile.
• Initial series suggest a higher pacemaker rate for the Sapien 3 compared with the preceding Sapien XT.
WHAT THE STUDY ADDS
• In this propensity score-matched analysis, the Sapien 3 performs better than the Sapien XT in terms of postoperative aortic regurgitation and vascular complications.
• Better valve patency was achieved with the Sapien 3, despite reduced oversizing, which may lower the risk of mechanical complications.
• A high implantation of the Sapien 3 is feasible and may provide similar pacemaker implantation rates compared with Sapien XT, compensating for the higher stent frame. during one slow inflation (5-10 s). Prosthesis position and function and patency of the coronary ostia were evaluated with angiography and intracardiac echocardiography or transesophageal echocardiography. Significant aortic regurgitation was addressed by postdilatation or second valve implantation, at discretion of the operator.
Statistical Analysis
Data were analyzed using IBM SPSS Statistics software version 20 (IBM Corp., Armonk, NY) and R version 2.12.0 (http://www.rproject.org). Continuous variables are presented as means±standard deviation or medians [interquartile range], as considered appropriate, and categorical variables as counts and percentages. Comparison of continuous variables between groups was performed with the Student's t test or Mann-Whitney test, depending on data distribution. Categorical variables were compared using Chi-square or Fisher's Exact test, as considered appropriate. Two-tailed P values <0.05 were considered statistically significant.
Propensity score matching was performed to adjust for differences in baseline characteristics between the S3-THV and the SXT-THV groups. The propensity score, reflecting the propensity of being treated with the S3-THV, was calculated by means of nonparsimonious binary logistic regression, including the following baseline features: age, sex, body mass index, hypertension, diabetes mellitus, glomerular filtration rate, coronary artery disease, peripheral artery disease, cerebrovascular disease, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, atrial fibrillation, chronic obstructive pulmonary disease, pulmonary hypertension, porcelain aorta, left ventricular ejection fraction, mean transaortic pressure gradient, baseline moderate to severe AR, and procedural access. The 2 groups were matched on the logit of the propensity score (caliper set to 0.20) using a greedy, nearest neighbor, one (S3-THV) to many (SXT-THV) matching algorithm. Balance diagnostics were performed by inspection of the weighted standardized mean differences (d) (<0.20 indicating adequate balance) as previously devised. 14 In the absence of expert consensus on the estimation of treatment effects in propensity score matching, the 2 matched groups were handled as unpaired independent groups. 15 Although all reported values for the matched control group represent unweighted data for transparency purposes, all statistical analyses were weighted for the number of matches.
Results
Between November 2011 and December 2014, out of 253 patients treated with TAVI because of severe symptomatic AS at the University Medical Center Utrecht, 168 (66.9%) received a balloon-expandable valve. One SXT-THV patient was excluded because of degenerated surgical valve disease, leaving 167 patients for further analysis. Forty-nine (29.3%) patients received a S3-THV (which was introduced in February 2014) and 118 (70.7%) a SXT-THV. Baseline characteristics, procedural features, and outcomes of the total population are provided in Tables I-III in the Data Supplement. The overall S3 and SXT-THV groups were comparable with respect to logistic EuroSCORE (median 15.8% versus 16.0%, P=0.899) and comorbidities. In the S3-THV group, there was a trend toward a lower incidence of renal impairment (49% versus 63%, P=0.088) and atrial fibrillation (25% versus 39%, P=0.084), with significantly lower left ventricular ejection fraction (48.5±12.4 versus 52.7±12.2%, P=0.043).
By means of one-to-many propensity score matching, 44 (89.8%) S3-THV patients were matched to 66 (55.9%) SXT-THV patients (1.5 matches per S3-THV patient on average). Baseline characteristics were well balanced, whereas imaging data showed differences between the matched groups (see Table 1 ). Aortic annuli were larger in the S3-THV group, demonstrated by the significantly larger diameter and area measurements on multislice computed tomography (all P<0.05). For each prosthesis size (23-mm, 26-mm, and 29-mm), larger annuli were treated with the S3-THV, with significantly lower percentage area and mean diameter oversizing (Figure 2A and 2B) .
The majority of S3-and SXT-THV patients were treated with transfemoral TAVI (77.3% and 78.8%) under local anesthesia. The S3-THV was implanted higher (ie, more aortic), indicated by the lesser percentage of stent frame height extending below the annulus plane (20.0±11.9 versus 31.0±11.7%, P<0.001) and lower implantation depth (4.0±2.2 versus 5.3±2.1 mm, P<0.001). Skewness of final valve position was smaller for the S3-THV (3.5±3.2 versus 5.3±3.8%, P=0.034). The incidence of postdilatation was comparable among the groups: 15.9% for the S3-THV and 12.1% for the SXT-THV (P=0.55). An overview of procedural features is provided in Table 2 .
Although not statistically significant, initial angiography showed a clear trend toward lower Grade ≥2+ AR (4.5% Figure 3A) . On final angiography, a significant difference in AR grade was observed, with lower Grade 1+ (13.6% versus 34.8%, P=0.002) and Grade 2+ AR (0% versus 6.1%, P=0.148) for the S3-THV ( Figure 3B ). No cases of grade 3 AR were recorded in any group. One case of coronary obstruction occurred in the S3-THV group (not because of the device, but because of compression of a diseased ostium of the right coronary artery by the deployment balloon), successfully treated with immediate PCI with stenting. Emergency surgery was required in one SXT-THV patient because of cardiac tamponade not resolved by subxiphoid pericardiocentesis. All patients in the S3-THV and 65 (98.5%) in the SXT-THV group underwent predischarge TTE. Peak and mean aortic transvalvular pressure gradients decreased significantly in both groups (both P<0.001), with no cases of residual stenosis. 
Comparison of Sapien 3 and Sapien XT
There was a significant difference in predischarge AR severity on TTE, with lower rates of mild AR (15.9% versus 38.5%, P=0.003) and moderate AR (0% versus 7.7%, P=0.075) in the S3-THV group ( Figure 3D) . No cases of severe AR were reported in any group. Figure 4 shows the comparative risk for ≥mild (or Grade I+) AR on angiography and predischarge TTE after TAVI. Exploratory univariable analysis for each valve type revealed percentage area and mean diameter oversizing as the only factors associated with ≥mild AR ( Table IV in the Data Supplement).
In-hospital clinical outcomes are presented in Table 3 . Numeric lower rates of life-threatening bleeding (2.3% versus 12.1%, P=0.083), major bleeding (2.3% versus 6.1%, P=0.70), and major vascular complications (4.5% versus 16.7%, P=0.044) were observed for the S3-THV. No lifethreatening or major bleedings neither major vascular complications were related to the transfemoral access site in the S3-THV group compared with 4 (7.7%) in the SXT-THV group (P=0.15). Pacemaker implantation rates were similar for both valves (9.8% versus 8.8%, P=0.94), and pacemaker indications exclusively comprised complete heart block. No differences in in-hospital and 30-day mortality were noted among the valves. In the S3-THV group, one in-hospital death was caused by hematothorax, leading to respiratory failure, whereas the second fatality was caused by postoperative mesenteric ischemia related to preexisting severe atherosclerosis (both transapical cases). In the SXT-THV group, the in-hospital deaths (all transfemoral cases) were caused by delayed valve embolization toward the left ventricle with acute heart failure and recurrent apnea of unknown origin (stroke was ruled out). One additional death occurred within 30-days in the SXT-THV group because of the late sequelae of an intraprocedural disabling stroke (transfemoral case). Weighted outcome data for the matched Sapien XT cohort are provided in Table III in the Data Supplement.
Discussion
The purpose of the present study was to compare the outcomes of the new balloon-expandable S3-THV with the preceding SXT-THV in TAVI for severe AS. All of the SXT-THV procedures were state-of-the-art: using the Novaflex+ deployment catheter and expandable sheaths. Main findings of this study are (1) a lower incidence of paravalvular AR for the S3-THV, in the presence of similar postdilatation rates and less extensive prosthesis to aortic annulus oversizing, (2) absence of major transfemoral access site bleedings and vascular complications for the S3-THV, and (3) similar pacemaker implantation rates for both valves.
Although the outcomes of TAVI have improved over the past years, the technique remained sensitive to complications related to the arterial introduction of large bore sheaths and the implantation of valve prostheses without suturing under direct sight. Unsurprisingly, the pivotal PARTNER IA trial evaluating TAVI with the first Sapien prosthesis against surgical aortic valve replacement showed higher rates of vascular complications and paravalvular AR. 2 Important progress in reducing vascular adverse events was made with the introduction of the subsequent SXT-THV, as demonstrated in the PARTNER IIB trial. 16 Unfortunately, the amount of downsizing established with the SXT-THV system did not reduce the rate of stroke, nor did prosthesis design positively impact paravalvular leakage. 16 Therefore, the S3-THV has been developed: a new THV that not only incorporates further miniaturizing of the delivery system, but also includes an outer sealing cuff at the bottom of the stent frame to reduce paravalvular AR. In addition, it comes with a sophisticated delivery system that offers better flexing and fine-tuning abilities to improve coaxial engagement and precise valve positioning. 5 The first reports on S3-THV short-term performance indicate that the refinements to valve and delivery system design paid off. 6, 13, 17 The prospective Sapien 3 safety and performance study demonstrated one of the lowest rates of stroke (2.7%), major vascular complications (5.3%), and mild (23.6%) and moderate AR (3.8%) to date in a combined population of transfemoral and transapical TAVI. 6 Our present results show similar trends for the S3-THV. More importantly, the S3-THV yielded results superior to the preceding SXT-THV in a matched population of TAVI patients, especially with respect to the incidence and severity of postprocedure AR.
Ever since the introduction of TAVI, postprocedural AR has been a major limitation of this technique and source of criticism from conservative cardiac surgeons. Local anatomic challenges (heavy cusp and LVOT calcifications), 18, 19 but also inappropriate valve sizing, cause incomplete apposition of the prosthesis stent to the aortic annulus, resulting in paravalvular leaks. Initial data reported ≥moderate AR ranging from 2% to 71% for balloon-expandable valves, achieved in the setting of echocardiographic valve sizing using unidirectional annular measurements. 20 The introduction of more precise multislice computed tomography-guided sizing led to a 50% reduction in the rate of ≥moderate AR. [21] [22] [23] Nevertheless, the incidence of ≥mild AR remained >55% in these series, 21, 22 comparable to the 46% observed in our SXT-THV group. Impressively, our present analysis found a nearly 3-fold lower ≥mild AR rate of 16% for the S3-THV, which is even lower than the 25% reported in the Sapien 3 performance study. A previous comparison of the S3-and SXT-THV reported a 6-fold (7 versus 41%) reduction in ≥mild paravalvular AR, however. 17 The reduction of postprocedure AR established with the S3-THV is of great importance because several studies demonstrated decreased survival for even mild AR. 24, 25 Although causality is difficult to substantiate in observational research, increased survival may be expected. It seems self-evident that the reduced rate of paravalvular AR is accomplished by improved annular sealing because the external cuff fills up irregularities in adjacent aortic annulus and LVOT boundaries. 13, 17 The sealing abilities of the cuff are to such an extent that minimal oversizing, just enough to provide sufficient anchoring of the valve, seems effective for producing excellent valve patency. Hence, the observed 43% reduction in annular area oversizing for the S3-THV compared with the SXT-THV in the present study. In the Sapien 3 registry, area oversizing (<7%) was even less than in our series (<11%). 6 Of note, reduced oversizing was not associated with higher prosthetic gradients or reduced effective orifice area for the S3-THV in the present analysis. Positive side-effect of less aggressive oversizing may be a reduced risk of related complications, such as annular rupture and conduction disturbances. 26, 27 Future implementation of the sizing recommendations derived from the Sapien 3 study may lead to even better results with the S3-THV in terms of valve patency.
Previous studies suggested a reduced postdilatation rate for the S3-THV 6,17 because the need for postdilatation ranges between 12% and 20% for the SXT-THV, 21, 28 whereas figures of only 3% to 4% have been reported for the S3-THV. 6, 17 Our 16% incidence of postdilatation for the S3-THV may be related to a lower threshold because mild AR was no longer regarded a satisfactory result as a result of anticipated valve performance and prognostic considerations. Another contributing factor to the postdilatation rate may have been a tendency toward incomplete S3-THV stent frame expansion or shortening, after initial placement, a phenomenon observed in our experience that may promote postdilatation in the presence of only mild AR. Because the S3-THV is less oversized, postdilatation may be regarded more safe with respect to mechanical complications. Postdilatation should not be performed lightheartedly, however, because there is evidence it may lead to an increase in cerebral embolic events. 29, 30 Whether it is advisable to postdilate in an attempt to further reduce mild AR to none remains to be determined.
Interestingly, our matched analysis found similar pacemaker implantation rates for the S3-and SXT-THV. Preliminary S3-THV data raised concerns of an increased pacemaker dependency because the increased valve height may lead to a larger portion of the stent frame extending in the LVOT, a well-known predictor of pacemaker implantations. 31, 32 The 9.8% pacemaker rate of S3-THV in this analysis and the 13.3% observed in the Sapien 3 performance study are indeed at the high end of what is usual for Sapien valves (median 6% [4] [5] [6] [7] in a recent meta-analysis), although rates vary considerably between studies. 33 In contrast, Tarantini and colleagues reported a seemingly excessive pacemaker rate of 20.7% for the S3-THV, which was related to an implantation depth ≥8 mm. 34 Only 2 of the S3-THVs in this study were implanted that deep (in one case leading to persistent complete heart block and pacemaker implantation). High placement of the S3-THV is preferable in our experience, not only to evade conduction disturbances associated with deep implantations, but also to take full advantage of the sealing properties of the external cuff when positioned within (or just below) the aortic annulus. In our S3-THV procedures, we aim for a 80/20 implantation (80% of stent frame height aortic and 20% ventricular), provided that aortic root anatomy accommodates an implantation this high (aortic sinuses should be sufficiently wide or coronary ostia located distally enough to avoid obstruction of the coronaries). To accomplish this, deployment of the S3-THV is initiated with the central marker just (≈1-2 mm) above the annular plane, exploiting a slow inflation technique (5-10 s to full inflation), which can be interrupted to allow small adjustments to valve position when needed (see Movies I and II in the Data Supplement). This precise valve positioning is facilitated by the S3-THV delivery system, in particular the fine-tuning knob for advancing or retracting the prosthesis, which may help to prevent out of range implantations. 13 In this regard, more coaxial engagement, as reflected in the reduced skewness of valve position in our series, provides additional value by safeguarding equally high valve placement at both margins of the aortic annulus.
The absence of transfemoral access site-related major vascular and bleeding complications observed for the S3-THV is likely related to reduced sheath size. Sheath size, and especially sheath external diameter to minimal femoral diameter artery ratio (≥1.05), has been previously associated with major vascular complications. 35 The 14 and 16-F sheaths of the S3-THV allow more margin with respect to this ratio and provide access to smaller vascular anatomies, which qualifies more patients to undergo safe transfemoral TAVI.
Limitations
Main limitations of this study are sample size and the retrospective, nonrandomized, single center design. Although propensity score matching is a well-accepted approach in observational research to address differences in baseline characteristics, it cannot account for unmeasured bias. In this regard, the extent and severity of native valve and LVOT calcification, both reported as predictors of post-TAVI AR, were not systematically recorded, and their potential impact on study results is therefore unknown. In addition, the SXT-THV group comprised historical controls because both THVs were not simultaneously used during the course of our TAVI program.
Conclusions
In this single-center, retrospective, propensity score-matched analysis, the new S3-THV demonstrated lower rates of postprocedure AR compared with the preceding SXT-THV. The reduction in both the incidence and severity of AR was achieved in the presence of less extensive prosthesis to aortic annulus oversizing, which may reduce the risk for annular rupture and conduction disturbances. Furthermore, the S3-THV was devoid of significant transfemoral access site-related bleeding and vascular complications. With its exceptionally low rate of complications, improved valve patency, and increased transfemoral access safety, the S3-THV seems to meet the demands for the further extension of TAVI to lower risk populations.
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